Lead Optimization Clause Samples
Lead Optimization. The Research Committee will update the Research Plan to provide for the accelerated lead optimization of the selected Committed Compound Sets with Committed Targets in the Collaboration, subject to Steering Committee approval. The Research Plan will set project priorities and define success criteria for a GLP Toxicology Candidate. As described in the Collaboration Plan, in a typical project the parties will iteratively develop and test Analog Compounds based on Committed Compounds. The parties will determine whether a proposed Analog Compound is an Available Compound before synthesis, and only Available Compounds will proceed to synthesis and testing in the Collaboration. The Analog Compounds developed by the parties shall automatically become Committed Compounds under this Agreement and, therefore, the Committed Compound Set for the Committed Target will likely expand as a result of the lead optimization efforts. At the discretion of the Research Committee, the parties may also use such Analog Compounds in primary screens against other ACADIA Targets. The parties anticipate that lead optimization of Committed Compounds will occur in two stages:
(i) In the first stage, the parties will develop Analog Compounds as combinatorial libraries to explore the promise of the Committed Compound Set for the Committed Target. The parties will test these Analog Compounds for various properties determined by the Research Committee to predict whether the Committed Compound Set may eventually meet the defined success criteria for a GLP Toxicology Candidate. The parties will decide whether to proceed to stage two for a given Committed Compound Set within [***].
(ii) In the second stage, the parties intend to concentrate their efforts on developing [***] and [***] corresponding Committed Compound Set(s) to identify a GLP Toxicology Candidate, with [***] from the first stage. The parties shall maintain a level of effort determined by the Research Committee for the [***]. The Research Committee may release Committed Targets and the corresponding Committed Compound Set(s) that are no longer of interest to the Collaboration or which are no longer the subject of the active efforts by the parties, as determined by the Research Committee and subject to Steering Committee approval, in which case the allocation provisions of Section 9.6. shall apply. Lead optimization activities will continue with respect to a Committed Target until the Research Committee and Steering Committee deci...
Lead Optimization. The term “
Lead Optimization. Pfizer shall propose to ArQule at least one (1) lead optimization program, the subject matter of which shall *, on which it will collaborate with ArQule during the Agreement Period. The Parties shall negotiate in good faith the terms and conditions of such lead optimization program in a separate agreement.
Lead Optimization. (a) Telik shall diligently undertake a maximum of [*] Lead Optimization Projects (as defined below) concurrent for Sanwa at any given time, each with respect to a Family of Compounds (as defined below) as Sanwa shall select by providing written notice to Telik. For a period of [*] commencing on [*], Telik shall undertake, [*], a Lead Optimization Project for the [*] Family of Compounds. If Telik completes such Lead Optimization Project in less than [*], or if Sanwa notifies Telik that it wishes to substitute another Lead Optimization Project in place of a previously selected Lead Optimization Project, Telik shall undertake such new or substitute Lead Optimization Project as Sanwa may select, taking into account the scientific advice of the "RMC," as such term is defined in the Collaboration Agreement between Telik and Sanwa dated December 20, 1996, as amended ("Collaboration Agreement"), by providing written notice to Telik, until the expiration of the above [*] period [*]. Telik shall also diligently undertake concurrent with the Lead Optimization Project for the [*] Family of Compounds a [*] Lead Optimization Project as selected by Sanwa including, for example, a Lead Optimization Project for the [*] Family of Compounds. If Sanwa requests that Telik undertake a [*] Lead Optimization Project at any time during the [*] period described above, or continue a Lead Optimization Project after the expiration of the [*] period described above, both after taking into account the scientific advice of the RMC, Sanwa shall pay Telik [*], working through the RMC.
(b) Upon commencement of the [*] of the Lead Optimization Project for the [*] Family of Compounds, Telik shall (i) devote the appropriate personnel, equipment and other resources as necessary to ensure that the Lead Optimization Project proceeds in such a manner as to allow Telik to apply for the patents referred to in Section 4.5 by the dates set forth therein and ensure the availability of Active Compounds and necessary information related thereto to enable Sanwa to use such Active Compounds in preclinical and clinical studies as soon as possible and (ii) identify the appropriate personnel, equipment and other resources as necessary to allow Telik to diligently undertake a [*] Lead Optimization Project. Subject to the following requirements with respect to a [*] Lead Optimization Project, Telik shall ensure [*] a [*] Lead Optimization Project that Telik shall undertake for Sanwa pursuant to this Section 1.4...
Lead Optimization. ▇▇▇▇▇▇▇ shall, concurrent with sending the Company Selection Notice, make the payment(s) to Cengent as indicated in Paragraph above. Also, Company shall pay $150,000 to Cengent upon selecting by Company of a Lead Optimization Compound or a derivative (e.g., homologs, analogs, polymorphs, isomers, prodrugs and formulations of the Lead Optimization Compound), payable as a number of shares of Company stock based on the most recent stock price accepted by an independent investor in an arm's length transaction.
Lead Optimization. As used herein "Lead Optimization" shall mean design and/or synthesis of new chemical entities based on a Lead Compound using Centaur's SAR program or other technologies for drug discovery and drug design in order to find compounds meeting CD Nomination Criteria.
Lead Optimization. During the Collaborative Research Term, the JRDC shall review and prioritize each Lead Compound on a regular basis, allocating the split of responsibilities and resources between the Parties with the goal of advancing a prioritized Lead Compound to Development Candidate by the conduct of the Lead Optimization Responsibilities set forth in the Research Plan, and the factors described below. In general, the responsibilities for [ * ] of a Lead Compound and associated [ * ] (including [ * ] and [ * ]) shall remain with [ * ] that [ * ] such [ * ]; provided, however, that the Parties may agree to allocate some activities (and transfer Lead Compounds) to [ * ] that [ * ] such [ * ] if [ * ] has [ * ] and [ * ] that are [ * ] to the [ * ] (e.g., in the areas of specific [ * ] or [ * ] models, [ * ] assets or access to [ * ])]. During the Collaborative Research Term, each Party shall [ * ] to [ * ] the [ * ] that are [ * ] to [ * ] by [ * ] and to update the JRDC with the progress and results of such conduct. The JRDC shall assess the status of the Lead Compounds, and, if a Lead Compound meets the Development Candidate Nomination Criteria, or if the JRDC otherwise determines that a Lead Compound should be advanced as a Development Candidate for preclinical development, then the JRDC shall nominate such Lead Compound as a Development Candidate to [ * ]. [ * ] shall promptly (and in good faith) review such nomination and determine whether such Lead Compound shall be advanced for preclinical development by becoming a Development Candidate. If [ * ] determines to approve such Lead Compound as a Development Candidate, then [ * ] shall promptly notify the JRDC, and such Lead Compound shall be deemed to be a Development Candidate and shall no longer be deemed to be a Lead Compound. [ * ] shall also determine which Party would be responsible for CMC Activities, preclinical development, IND submission and conduct of the first Phase I Clinical Trial for such Development Candidate. If the JRDC decides not to nominate a Lead Compound as a Development Candidate, or if [ * ] does not approve a Lead Compound as a Development Candidate, and the JRDC [ * ] recommends additional work to be performed on such Lead Compound, then, [ * ] that [ * ] such [ * ] shall use Diligent Efforts to conduct such additional work and re-submit such Lead Compound to the JRDC; provided, however, that the JRDC shall have the sole discretion to prioritize such additional work relative to any work bein...
Lead Optimization. The third stage of the Discovery Optimization Program will progress one of the Targets through lead optimization to identify qualified Active Compounds [*****]. During this stage of the program, [*****] of Derivative Compound synthesis and optimization will be executed[*****].
Lead Optimization. Lead optimization activities will consist of the iterative synthesis and testing of Collaboration Compounds (including Analog Compounds within a Collaboration Compound Set) to identify one or more lead compounds that exhibit acceptable activity and selectivity for a Collaboration Target or other anti-infective activity if the molecular target is unknown, as well as exhibiting inhibition of bacterial growth or bactericidal activity, favorable ADMET characteristics (including minimal toxicity and oral bioavailability and an acceptable pharmacokinetic profile), and in vivo efficacy with an acceptable therapeutic index in an appropriate *****. The Parties hope that one or more of the Collaboration Compound Sets will progress through lead optimization to identify at least one GLP Toxicology Candidate. During this phase of the program, several iterations of analog synthesis and optimization will be executed in parallel with in vitro ADMET profiling, biological assays for potency and selectivity, and in vivo testing in animal models as appropriate.
Lead Optimization. Telik shall diligently undertake a maximum of [ * ] Lead Optimization Projects (as defined below) simultaneously at any given time, each with respect to a Family of Compounds (as defined below) as Sanwa shall select taking into account the scientific advice of the "RMC," as such term is defined in the Collaboration Agreement between Telik and Sanwa dated December 20, 1996, as amended ("Collaboration Agreement"), by providing written notice to Telik. For a period of two years, commencing on the date of written notice from Sanwa identifying the Family of Compounds for a Lead Optimization Project, [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to rule 406 of the Securities Act of 1933, as amended.
1. Telik shall undertake, [ * ] such Lead Optimization Project. If Telik completes such Lead Optimization Project in less than two (2) years, or if Sanwa notifies Telik that, taking into account the scientific advice of the RMC, it wishes to substitute another Lead Optimization Project in place of a previously selected Lead Optimization Project, Telik shall undertake such new or substitute Lead Optimization Project as Sanwa may select, taking into account the scientific advice of the RMC, by providing written notice to Telik, until the expiration of the above two (2) year period [ * ] If Telik undertakes a [ * ] Lead Optimization Project as selected by Sanwa, or continues with the Lead Optimization Project after the expiration of the two (2) year period described above, both after taking into account the scientific advice of the RMC, Sanwa shall pay Telik [ * ], working through the RMC. Telik shall ensure [ * ] and to [ * ] that Telik shall undertake for Sanwa pursuant to this Section 1.4.